Clinical trials · KRAS G12C

KRAS G12C clinical trials in non-small cell lung cancer

The 50 trials Atlas ranked most relevant to KRAS G12C in lung cancer, from first-in-human studies to 8 phase 3 trials, with the phase, status, sponsor and enrollment of each, as registered on ClinicalTrials.gov.

Example project: KRAS G12C · non-small cell lung cancerChecked on ClinicalTrials.gov · 30 Oct 2026
most relevant trials on KRAS G12C
50
KRAS G12C inhibitors tested
6
phase 3 trials
8
trials recruiting, about to start or ongoing
27

KRAS G12C trials at a glance

Trials by KRAS G12C inhibitor

InhibitorTrialsPhase 3Open, starting or ongoingMost frequent lead sponsor
Sotorasib1919No single sponsor leads16 lead sponsors in total
Adagrasib1628Mirati Therapeutics Inc.7 lead sponsors in total
Divarasib635Hoffmann-La Roche2 lead sponsors in total
Olomorasib423Eli Lilly and Company3 lead sponsors in total
Glecirasib403No single sponsor leads4 lead sponsors in total
Fulzerasib200Innovent Biologics (Suzhou) Co. Ltd.

The 50 trials

Sorted by phase, then by enrollment. Interventions and sponsors are shown as registered; the list of other interventions does not say which drug is a comparator. Each NCT number opens the registry record.

TrialKRAS G12C inhibitorOther interventionsPopulationPhaseStatusLead sponsorStartEnrollment
NCT06119581SUNRAY-01OlomorasibLY3537982Pembrolizumab, cisplatin, carboplatin, pemetrexed, placeboNSCLCPhase 3RecruitingEli Lilly and CompanyDec 20231,264
NCT05920356CodeBreaK 202SotorasibPembrolizumab, platinum doubletNSCLCPhase 3RecruitingAmgenNov 2023750
NCT06890598SUNRAY-02OlomorasibPembrolizumab, durvalumab, placeboNSCLCPhase 3RecruitingEli Lilly and CompanyMar 2025700
NCT06875310KRYSTAL-4AdagrasibPembrolizumab, carboplatin, cisplatin, pemetrexed, placeboNSCLCPhase 3RecruitingMirati Therapeutics Inc.Apr 2025630
NCT06793215Krascendo 2DivarasibPembrolizumab, carboplatin, cisplatin, pemetrexedNSCLCPhase 3RecruitingHoffmann-La RocheOct 2025600
NCT04685135KRYSTAL-12AdagrasibMRTX849DocetaxelNSCLCPhase 3Active, not recruitingMirati Therapeutics Inc.Feb 2021453
NCT07541170Krascendo 3DivarasibPembrolizumab, nivolumabNSCLCPhase 3RecruitingHoffmann-La RocheOct 2026400
NCT06497556Krascendo 1DivarasibSotorasib, adagrasibNSCLCPhase 3Active, not recruitingHoffmann-La RocheSep 2024338
NCT04613596KRYSTAL-7AdagrasibPembrolizumabNSCLCPhase 2/3RecruitingMirati Therapeutics Inc.Dec 2020626
NCT05853575KRYSTAL 21AdagrasibTwo dosing regimensNSCLCPhase 2Active, not recruitingMirati Therapeutics Inc.Feb 2024200
NCT04625647Lung-MAPSotorasibAMG 510None (monotherapy)NSCLCPhase 2Active, not recruitingSWOG Cancer Research NetworkApr 2021116
NCT05311709SOLUCOMSotorasibNone (patients with comorbidities)NSCLCPhase 2UnknownVestre Viken Hospital TrustMay 2022100
NCT05609578AdagrasibPembrolizumab, pemetrexed, cisplatin or carboplatinNSCLCPhase 2Active, not recruitingMirati Therapeutics Inc.Nov 202290
NCT07164170GlecirasibABSK043NSCLCPhase 2RecruitingAbbisko Therapeutics Co, LtdSep 202586
NCT07639242OlomorasibPembrolizumabNSCLCPhase 2SuspendedUNC Lineberger Comprehensive Cancer CenterOct 202660
NCT04933695CodeBreaK 201SotorasibNone (first line, monotherapy)NSCLCPhase 2TerminatedAmgenJan 202242
NCT06582771SotorasibNone (monotherapy)NSCLCPhase 2RecruitingMemorial Sloan Kettering Cancer CenterAug 202439
NCT05451056SotorasibNone (with a resistance translational study)NSCLCPhase 2UnknownYonsei UniversityAug 202237
NCT07827261GlecirasibBL-B01D1NSCLCPhase 2Not yet recruitingSichuan Baili Pharmaceutical Co., Ltd.Sep 202636
NCT06248606AdagrasibStereotactic radiosurgery (untreated brain metastases)NSCLCPhase 2RecruitingRyan Gentzler, MDAug 202430
NCT07543172Adagrasib or SotorasibCIMAvax-EGFNSCLCPhase 2Not yet recruitingRoswell Park Cancer InstituteOct 202629
NCT05118854SotorasibCisplatin or carboplatin, pemetrexed (neoadjuvant)NSCLCPhase 2Active, not recruitingM.D. Anderson Cancer CenterMar 202213
NCT06333678SotorasibDurvalumabNSCLCPhase 2TerminatedMemorial Sloan Kettering Cancer CenterMar 202410
NCT05472623Neo-KanAdagrasibNivolumab (neoadjuvant)NSCLCPhase 2WithdrawnSidney Kimmel Comprehensive Cancer Center at Johns HopkinsMar 20230
NCT05400577SotorasibNone (neoadjuvant, resectable stage IB–IIIA)NSCLCPhase 2WithdrawnFox Chase Cancer CenterJul 20220
NCT05815186SotorasibLadarixinNSCLCPhase 2WithdrawnNYU Langone HealthApr 20240
NCT05005234FulzerasibGFH925NoneSolid tumorsPhase 1/2CompletedInnovent Biologics (Suzhou) Co. Ltd.Sep 2021334
NCT05789082Krascendo 170DivarasibPembrolizumab, carboplatin, cisplatin, pemetrexedNSCLCPhase 1/2RecruitingHoffmann-La RocheJun 2023320
NCT05074810RAMP 203SotorasibAvutometinib, defactinibNSCLCPhase 1/2Active, not recruitingVerastem, Inc.Apr 2022153
NCT07227025KaRAnaSaOlomorasibAmivantamabNSCLCPhase 1/2RecruitingJanssen Research & Development, LLCMar 202660
NCT07339839GlecirasibIvonescimabNSCLCPhase 1/2Not yet recruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesMar 202642
NCT07012031SotorasibTrastuzumab deruxtecanNSCLCPhase 1/2RecruitingNational Cancer Institute (NCI)Jun 202637
NCT05002270GlecirasibJAB-21822CetuximabSolid tumorsPhase 1/2CompletedJacobio Pharmaceuticals Co., Ltd.Sep 202129
NCT05375994RAMP 204AdagrasibAvutometinibNSCLCPhase 1/2CompletedVerastem, Inc.Aug 202212
NCT05313009SotorasibTarloxotinibNSCLCPhase 1/2TerminatedMedical University of South CarolinaMar 20225
NCT06024174AdagrasibBMS-986466, cetuximabSolid tumorsPhase 1/2TerminatedBristol-Myers SquibbNov 20235
NCT04449874DivarasibGDC-6036Atezolizumab, cetuximab, bevacizumab, erlotinib, GDC-1971, inavolisibSolid tumorsPhase 1Active, not recruitingGenentech, Inc.Jul 2020498
NCT04330664KRYSTAL 2AdagrasibMRTX849TNO155Solid tumorsPhase 1CompletedMirati Therapeutics Inc.Apr 202086
NCT05815173SotorasibLadarixinNSCLCPhase 1RecruitingNYU Langone HealthAug 202340
NCT05480865ArgonautSotorasibBBP-398Solid tumorsPhase 1TerminatedNavire Pharma Inc., a BridgeBio companyJul 202228
NCT07382726IZA-AAdagrasibIzalontamab brengitecanNSCLCPhase 1RecruitingM.D. Anderson Cancer CenterMay 202618
NCT06249282SotorasibCarfilzomibNSCLCPhase 1RecruitingCity of Hope Medical CenterApr 202415
NCT05497336FulzerasibIBI351CetuximabColorectal cancerPhase 1TerminatedInnovent Biologics (Suzhou) Co. Ltd.Aug 20228
NCT04975256KRYSTAL 14AdagrasibMRTX849BI 1701963Solid tumorsPhase 1TerminatedMirati Therapeutics Inc.Jul 20217
NCT05840510KRYSTAL-19Adagrasibnab-SirolimusSolid tumorsPhase 1TerminatedMirati Therapeutics Inc.Aug 20236
NCT05374538SotorasibVIC-1911NSCLCPhase 1TerminatedVitrac Therapeutics, LLCNov 20223
NCT06130254AdagrasibOlaparibSolid tumorsPhase 1TerminatedM.D. Anderson Cancer CenterJan 20241
NCT05848843AdagrasibDurvalumabNSCLCPhase 1WithdrawnM.D. Anderson Cancer CenterApr 20230
NCT05273047LungKG12CiSotorasibNone (real-world, observational)NSCLCNot applicableUnknownIntergroupe Francophone de Cancerologie ThoraciqueMar 2022458
NCT07783009DivarasibNone (expanded access program)NSCLCNot applicableExpanded accessGenentech, Inc.——

How this list was built

We created one Atlas project with the disease “Non-small cell lung cancer”, the target “KRAS G12C” and the keywords “KRAS G12C inhibitor, sotorasib, adagrasib, divarasib, olomorasib, glecirasib”, with precision mode on. Atlas searched the registry, scored each trial against the project and kept 50 of them in the corpus, built on 10 Oct 2026. We then read each of those records on ClinicalTrials.gov again on 30 Oct 2026; phase, status and enrollment are the registry’s values on that date.

These are the 50 most relevant trials, not every trial. Precision mode keeps at most 50 trials per project, ranked by how closely each one matches the disease, the target and the keywords. ClinicalTrials.gov returns about 130 studies for “KRAS G12C” in non-small cell lung cancer (30 Oct 2026), many of which enroll KRAS G12C patients as one cohort among other mutations or tumor types. A project without that limit, or with a narrower question, retrieves more.

40 of the trials are lung cancer studies. 9 enroll several solid tumors and are listed because they include KRAS G12C lung cancer; 1 is a colorectal cancer study, kept by the project for the inhibitor it tests rather than the disease. The list covers ClinicalTrials.gov only: trials registered solely in other registries do not appear. It describes registry records, not results, and is not medical advice. Patients looking for a trial should start from ClinicalTrials.gov and their care team.

The same project is analyzed on the clinical trial landscape page, with phases, statuses and the stated reasons the stopped trials stopped. The registries and literature sources Atlas reads are listed on data sources.

Get this table for your own target

We set up an Atlas project on your disease and target with you, and you get the trials, the papers and the evidence behind them in one place.

Request a demo

Source: ClinicalTrials.gov API v2, records read on 30 Oct 2026 for the 50 trials of the Atlas project “KRAS G12C NSCLC Landscape”. Enrollment is the registered target or actual count. Registry data changes; check the record before relying on a value. This table is published under CC BY 4.0: reuse it freely, crediting Helix Research Intelligence with a link to this page.